Insulet Corporation (PODD)

Currency in USD
154.61
+2.12(+1.39%)
Closed·
155.00+0.39(+0.25%)
·
PODD is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
150.74158.32
52 wk Range
145.59354.88
Key Statistics
Prev. Close
152.49
Open
153.23
Day's Range
150.74-158.32
52 wk Range
145.59-354.88
Volume
1.39M
Average Volume (3m)
1.22M
1-Year Change
-52.7865%
Book Value / Share
18.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
246.79
Upside
+59.62%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Insulet Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

21 Buy
3 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 246.79
(+59.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy250.00+61.70%-MaintainMay 11, 2026
Barclays
Sell198.00+28.06%286.00MaintainMay 08, 2026
JPMorgan
Buy275.00+77.87%340.00MaintainMay 07, 2026
Wells Fargo
Buy255.00+64.93%360.00MaintainMay 07, 2026
Stifel
Buy250.00+61.70%350.00MaintainMay 07, 2026

Insulet Corporation SWOT Analysis


Patch Pump Pionee
Insulet leads the insulin pump market with its innovative Omnipod 5 platform, boasting a $21.58 billion market cap and impressive 70.39% gross margins
Financial Triumph
Explore Insulet's record-breaking Q1 2025 performance, with 30% worldwide growth and raised 2025 revenue guidance to 19-22%, signaling strong market momentum
Market Expansion
Delve into Insulet's strategic moves in the Type 2 diabetes market and international expansion, unlocking vast growth potential in underpenetrated segments
Analyst Optimism
Discover why analysts project bullish price targets ranging from $266 to $365, reflecting confidence in Insulet's technological advancements and market position
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $1.42 beat estimates by 18.3%; revenue reached $761.7M, exceeding forecasts by 4.4% with 34% YoY growth driven by Omnipod sales.
  • GAAP gross margin hit 69.5% while adjusted operating margin improved 110 basis points to 17.5%, reflecting strong operational execution.
  • Stock declined 0.3% premarket to $167.02 despite earnings beat; shares down 48% over six months, trading near 52-week low of $158.35.
  • Company guided Q2-Q4 2026 EPS between $1.48-$2.02 and revenue of $788M-$935M; announced Omnipod 5 integration with FreeStyle Libre 3 Plus.
  • Management cited innovation focus and market expansion plans; acknowledged margin pressure risks from exit costs and supply chain disruptions.
Last Updated: 2026-05-06, 09:34 a/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
1.42 / 1.20
Revenue / Forecast
761.7M / 729.9M
EPS Revisions
Last 90 days

PODD Income Statement

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
35.4x8.4x−0.5x
PEG Ratio
−1.560.030.00
Price/Book
8.2x6.1x2.6x
Price / LTM Sales
3.7x3.8x3.1x
Upside (Analyst Target)
61.4%52.2%55.1%
Fair Value Upside
Unlock16.3%7.2%Unlock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
43.37M62.61%6.71B
Other Institutional Investors
26.76M37.39%4.14B
Public Companies & Retail Investors
0.000.00%0.00
Total
70.13M100.00%10.84B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.12.56%8,701,4721,345,335
BlackRock, Inc.9.49%6,576,6551,016,817

People Also Watch

50.88
CTSH
-1.01%
56.03
FISV
-1.11%
25.46
GTLB
+1.47%
399.71
INTU
-0.86%
32.56
CTRA
-8.62%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 154.61 USD.

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 10.71B USD.

What Is Insulet's Earnings Per Share (TTM)?

The Insulet EPS (TTM) is 4.29.

When Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times.

How Many Employees Does Insulet Have?

Insulet has 5400 employees.

What is the current trading status of Insulet (PODD)?

As of May 20, 2026, Insulet (PODD) is trading at a price of 154.61 USD, with a previous close of 152.49 USD. The stock has fluctuated within a day range of 150.74 USD to 158.32 USD, while its 52-week range spans from 145.59 USD to 354.88 USD.

What Is Insulet (PODD) Price Target According to Analysts?

The average 12-month price target for Insulet is 246.79 USD, with a high estimate of 360 USD and a low estimate of 175 USD. 21 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +59.62% Upside potential.

What Is the PODD Premarket Price?

PODD's last pre-market stock price is 151.91 USD. The pre-market share volume is 360.00, and the stock has decreased by -0.58, or -0.38%.

What Is the PODD After Hours Price?

PODD's last after hours stock price is 155.00 USD, the stock has decreased by 0.39, or 0.25%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.